» Articles » PMID: 9131261

Medication Compliance As a Feature in Drug Development

Overview
Publisher Annual Reviews
Specialties Pharmacology
Toxicology
Date 1997 Jan 1
PMID 9131261
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Well-designed clinical trials maximize the information that can be obtained regarding the clinical pharmacology of a drug and, in turn, can streamline and enhance the drug development process. Until recently, little emphasis has been placed on integrating the role of variability in individual patterns of drug-taking into the drug development process. With the use of electronic monitoring, the temporal relationship between an individual's pattern of dosing and the prescribed regimen may be examined, and individual drug exposure may be estimated based on the actual history of dosing. As a result, accurate estimation of exposure-response relationships (or surrogate markers of response) can be obtained. Considerations in the design of clinical trials must therefore be expanded to include appropriate methods to measure compliance, sufficient frequency of monitoring to allow the time course of response to be mapped, and the use of statistically valid methods of data analysis.

Citing Articles

How the EMERGE guideline on medication adherence can improve the quality of clinical trials.

Eliasson L, Clifford S, Mulick A, Jackson C, Vrijens B Br J Clin Pharmacol. 2020; 86(4):687-697.

PMID: 32034923 PMC: 7098872. DOI: 10.1111/bcp.14240.


A Systematic Evaluation of Effect of Adherence Patterns on the Sample Size and Power of a Clinical Study.

Mallayasamy S, Chaturvedula A, Blaschke T, Fossler M CPT Pharmacometrics Syst Pharmacol. 2018; 7(12):818-828.

PMID: 30291680 PMC: 6310871. DOI: 10.1002/psp4.12361.


The clinical utility of the Medication Adherence Questionnaire (MAQ) in an alcohol pharmacotherapy trial.

Zweben A, Piepmeier M, Fucito L, OMalley S J Subst Abuse Treat. 2017; 77:72-78.

PMID: 28476276 PMC: 5480370. DOI: 10.1016/j.jsat.2017.04.001.


Riboflavin as an independent and accurate biomarker for adherence in a randomized double-blind and placebo-controlled clinical trial.

Ramanujam V, Nayeem F, Anderson K, Kuo Y, Chen N, Ju H Biomarkers. 2016; 22(6):508-516.

PMID: 27918196 PMC: 5613754. DOI: 10.1080/1354750X.2016.1269201.


Riboflavin as an oral tracer for monitoring compliance in clinical research.

Ramanujam V, Anderson K, Grady J, Nayeem F, Lu L Open Biomark J. 2011; 2011(4):1-7.

PMID: 21949554 PMC: 3176727. DOI: 10.2174/1875318301104010001.